The pharmaceutical industry criticizes the plan to pricing the drugs that Trump will sign

Washington – President Donald Trump’s plan to modify the pricing model for certain drugs is already faced with fierce criticism from the pharmaceutical industry before even signing the executive decree for Monday which, if implemented, could reduce the cost of certain drugs.

Trump has promised that his plan – which is likely to link the price of drugs covered by health insurance and administered in a doctor’s office at the lowest price paid by other countries – will considerably reduce medication costs.

“I will institute the most favored nation policy by which the United States will pay the same price as the nation that pays the lowest prize in the world,” the Republican president on social networks published on Sunday, committing to sign the order on Monday morning at the White House.

But the country’s first pharmaceutical lobby postponed on Sunday, calling it a “bad deal” for American patients. Medicines manufacturers have long argued that any threat to their profits could have an impact on the research they do to develop new drugs.

“Importing foreign prices will reduce billions of dollars of drugs without guarantee that it helps patients or improves their access to drugs,” said Stephen J. Ubl, president and chief executive officer of Phrma, in a statement. “It endangers the hundreds of billions of people that our member companies plan to invest in America, which makes us more dependent on China for innovative drugs.”

Trump’s “most favored nation’s” approach to the Pricing Medicare Pricing has been controversial since he tried to implement it during his first mandate. He signed a similar decree in the last weeks of his presidency, but an order of the court then prevented the rule of entering into force within the framework of the administration of President Joe Biden.

The pharmaceutical industry argued that Trump’s attempt in 2020 would give foreign governments the “above” to decide the value of drugs in the United States

It is likely that Trump’s decree on Monday will have only an impact on drugs covered by Medicare Part B, insurance for visits to the doctor’s office. Medicare beneficiaries are responsible for recovering some of the costs to obtain these drugs during visits to the doctor and traditional medication registrants, there is no annual ceiling on what they pay.

A report by the First Trump Administration has revealed that the United States spends twice as much as some other countries to cover these drugs. Medicare -shaped B -share medicine expenditure exceeded $ 33 billion in 2021.

Trump played the announcement, saying that it would allow taxpayers to save a lot of money.

“Our country will finally be treated fairly, and the costs of citizens’ health care will be reduced by the figures never thought before,” added Trump.

But many Americans will not see the savings.

Trump’s proposal would probably have an impact only on certain drugs covered by health insurance and given in an office – think of the infusions that treat cancer and other injectables. But that could potentially bring billions of dollars in savings to the government – not necessarily the “billions of dollars” that Trump has boasted in his position.

Medicare provides health insurance to around 70 million older Americans. Complaints concerning the prices of American drugs being notoriously high, even compared to other large rich countries, have long attracted the anger of the two main political parties, but a lasting solution has never eliminated the congress.

More common prescription drugs filled in a pharmacy would probably not be covered by the new order.

Trump’s post officially previewed the action occurred after teasing a “very big announcement” last week. He gave no details, except to note that he was not linked to the trade or the prices he announced for a large part of the world.

“We are going to have a very, very big announcement to make – as much as possible,” said Trump last week.

He entered his first mandate which accused the pharmaceutical companies of “fleeing with murder” and of complaining that other countries whose governments have set the prices of medicines benefited from the Americans.

On Sunday, Trump targeted the industry again, by writing that “pharmaceutical / pharmaceutical companies would say, for years, that these are research and development costs, and that all these costs were, and would, without any reason, be borne by the ‘` `discharges of America, alone.”

Referring to the powerful lobbying efforts of pharmaceutical companies, he said that the contributions of the campaign “can do wonders, but not with me, and not with the republican party”.

“We are going to do the right thing,” he wrote.